Search results
Results from the WOW.Com Content Network
Some drugs may be legally classified as over-the-counter (i.e. no prescription is required), but may only be dispensed by a pharmacist after an assessment of the patient's needs or the provision of patient education. Regulations detailing the establishments where drugs may be sold, who is authorized to dispense them, and whether a prescription ...
Sterne was the first to try metformin on humans for the treatment of diabetes; he coined the name "Glucophage" (glucose eater) for the medication and published his results in 1957. [ 161 ] [ 168 ] Metformin became available in the British National Formulary in 1958.
A 2020 meta-analysis of 21 trials found that metformin treatment could reduce BMI by one unit. Beyond weight loss, there are more metformin benefits, including anti-tumor effects, and reducing the ...
5. Metformin. Metformin — a biguanide — is an oral diabetes medication that helps keep blood sugar in check by causing the liver to produce less glucose. It was approved by the FDA in 1994 for ...
Vildagliptin is indicated, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes as monotherapy in people in whom metformin is inappropriate due to contraindications or intolerance; and in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycemic control.
Canagliflozin is indicated to be used with diet and exercise to lower blood sugar in adults with type 2 diabetes; to reduce the risk of major heart-related events such as heart attack, stroke, or death in people with type 2 diabetes who have known heart disease; and to reduce the risk of end-stage kidney disease, worsening of kidney function, heart-related death, and being hospitalized for ...
Adults with mild type 2 diabetes might improve their insulin sensitivity by following a low-carb diet, thus potentially eliminating the need for medication, a new study suggests.
Alogliptin, sold under the brand names Nesina and Vipidia, [2] [3] is an oral anti-diabetic drug in the DPP-4 inhibitor (gliptin) class. [4] Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of hypoglycemia, and has relatively modest glucose-lowering activity. [1]